ResMed Sees Nothing but ‘Tailwind’

The impact of GLP-1 drugs on the CPAP therapy market has stolen the headlines recently, but ResMed Chairman and CEO Mick Farrell says the impact of wearables might be “a higher tidal wave.” Farrell, on a recent conference call to discuss the company’s financial results for the third quarter of its fiscal year 2024, noted the Samsung Galaxy Watch’s recent de novo authorization from the U.S. Food and Drug Administration to detect signs of sleep apnea – a development that has the potential to significantly increase the number of people seeking CPAP therapy. “I think this might actually be a higher tidal wave than the big pharma tidal wave,” he said.

Read the full article: ResMed Sees Nothing but ‘Tailwind’ //


Leave a Comment

Your email address will not be published.

Scroll to Top